Seres Therapeutics

Seres Therapeutics(MCRB)

CAMBRIDGE, MA
Biotechnology2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Microbial drugs to counteract antibiotic side effects

Seres Therapeutics is a life sciences company focused on Microbial drugs to counteract antibiotic side effects.

Infectious Diseases
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/A
Phase 1
Clinical Trials (1)
NCT04995653A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Phase 1
Placebo for antibiotic
Metastatic Melanoma
Phase 1
Clinical Trials (1)
NCT03817125Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Phase 1
Phase 1
Clinical Trials (1)
NCT02618187A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Phase 1
Phase 1
Clinical Trials (1)
NCT02830542SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
Phase 1
Vancomycin Pre-Treatment
Ulcerative Colitis
Phase 2
Clinical Trials (1)
NCT03759041A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Phase 2
Phase 2
Clinical Trials (1)
NCT02437487SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
Phase 2
Phase 3
Clinical Trials (1)
NCT03183141ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Phase 3
Phase 3
Clinical Trials (1)
NCT03183128ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2013
Portfolio: 9 clinical trials
H-1B (2023): 2 approvals
SEC Filings: 2 available

Financials (FY2025)

Revenue
$0
R&D Spend
$118M7%
Net Income
-$114M
Cash
$31M
Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub